Skip to main content

Table 1 Clinical and serological characterization of the SLE patients, matched controls, and suggested aPL+ and SSA/SSB+ SLE subgroups

From: Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren’s syndrome differ in molecular signatures and treatment perspectives

 

Controls

n = 316 1

SLE

n = 378 1, 2

aPL+ SLE

n = 66 1

SSA/SSB+ SLE n = 63 1

Control vs.

aPL+ SLE p value 3

Control vs.

SSA/SSB+ SLE p value 3

aPL+ vs.

SSA/SSB+ SLE p value 3

Demographic/clinical

 Sampling age

48.1 (11.5)

47.7 (11.8)

47.9 (9.99)

48.6 (11.6)

8.7E−01

7.9E−01

9.8E−01

 Gender (%female)

92.1 (−)

87.3 (−)

83.3 (−)

84.1 (−)

3.6E−02

5.7E−02

1.0E+00

 Nephritis (%yes)

0.316 (−)

42.3 (−)

48.5 (−)

20.6 (−)

5.0E−27

3.0E−10

1.5E−03

 SLEDAI-2K

4 (3.5)

4 (3)

3 (2.75)

1.6E−02

 SLAM

6 (3)

6 (3.5)

7 (2.5)

7.4E−01

 SLICC total

1 (1)

2 (1.5)

1 (1)

1.1E−02

 Disease duration

11.6 (8.81)

10.3 (9.52)

8.42 (9.01)

8.2E−01

Serological/biochemical

 A1-antitrypsin (g/l)

1.4 (0.15)

1.4 (0.15)

1.5 (0.2)

1.4 (0.125)

8.7E−06

4.6E−01

3.3E−03

 Apo A (g/l)

1.7 (0.25)

1.5 (0.2)

1.4 (0.15)

1.4 (0.15)

3.3E−07

5.3E−06

5.0E−01

 Apo B (g/l)

0.81 (0.155)

0.81 (0.135)

0.83 (0.125)

0.79 (0.159)

1.5E−01

7.9E−01

2.2E−01

 C1q (% of normal)

103 (17.6)

101 (19.2)

105 (22)

5.5E−01

 C2 (% of normal)

118 (25.8)

105 (24)

144 (28.2)

1.4E−05

 C3 (g/l)

1.04 (0.145)

0.87 (0.165)

0.8 (0.135)

0.91 (0.149)

4.6E−14

5.5E−09

1.8E−01

 C3a (μg/l)

298 (1620)

270 (3586)

759 (1582)

1102 (1852)

6.8E−01

4.3E−01

3.6E−01

 C3dg (mg/l)

7.6 (2.05)

9.2 (1.93)

6.1 (1.58)

2.7E−05

 C4 (g/l)

0.21 (0.04)

0.15 (0.05)

0.125 (0.045)

0.15 (0.0338)

1.0E−17

3.9E−13

9.5E−02

 TCC (AU/l)

30 (25)

59 (153)

65 (57)

78 (74)

2.7E−04

3.4E−05

2.7E−01

 Creatinine (μmol/l)

66 (11)

69 (80)

72 (83)

69 (70)

5.6E−06

1.1E−02

8.2E−02

 SLEDAI-2K

Proteinurea = 4 (n)

39 (10%)

11 (17%)

3 (5%)

3.1E−02

 Fibrinogen (g/l)

3.8 (0.6)

4.1 (0.8)

4.5 (0.65)

4.1 (0.8)

4.4E−08

9.9E−02

8.8E−03

 Homocysteine (μmol/l)

9.3 (1.48)

12 (2.69)

13.6 (3.2)

11.3 (2.32)

3.6E−13

1.9E−08

1.1E−01

 Hs CRP (mg/l)

0.96 (0.825)

1.7 (2.22)

2.5 (3.73)

1.8 (2.26)

1.5E−08

1.7E−04

5.3E−02

 ESR

8.5 (8)

19 (22)

31 (25)

29 (30)

2.2E−16

2.2E−16

7.5E−1

 IgA (g/l)

2.1 (0.674)

2.8 (0.938)

2.65 (1.04)

2.9 (1.2)

3.8E−03

1.6E−04

4.8E−01

 IgG (g/l)

10.9 (1.35)

12.8 (3.18)

12.6 (3.19)

16 (5.18)

1.0E-05

6.1E−12

5.4E−03

 IgM (g/l)

1 (0.393)

0.93 (0.414)

1.2 (0.526)

0.82 (0.268)

7.1E−01

1.0E−04

8.1E−03

 RF-IgA (IU/ml)

3.7 (1.8)

5.3 (3.8)

5.7 (2.4)

29.5 (30.6)

3.1E−03

1.3E−10

1.5E−05

 RF-IgG (μg/ml)

7.5 (3.2)

11.0 (6.5)

11.0 (6.4)

26.0 (20.5)

2.3E−03

6.4E−10

9.1E−04

 RF-IgM (IU/ml)

1.1 (0.6)

1.3 (2.2)

1.2 (0.9)

10.5 (14.6)

0.7

4.2E−15

2.1 E−08

 Leucocytes (× E9/l)

5.5 (1)

5.1 (1.55)

5.5 (1.7)

4.8 (1.35)

6.4E−01

4.9E−05

1.8E−02

 Lymphocytes (× E9/l)

1.8 (0.3)

1.1 (0.35)

1.1 (0.362)

0.9 (0.275)

9.6E−17

5.7E−23

1.5E−01

 Neutrophils (× E9/l)

3 (0.8)

3.2 (1.3)

3.55 (1.46)

3.2 (1.17)

3.4E−02

2.8E−01

2.7E−02

 Platelets (× E9/l)

260 (36.5)

234 (50)

219 (47)

225 (61.8)

7.4E−06

8.0E−03

1.9E−01

 TG mmol/l)

0.77 (0.275)

1 (0.355)

1.4 (0.385)

0.9 (0.34)

1.2E−10

1.1E−02

1.5E−03

 VCAM (μg/l)

364 (71)

388 (95)

444 (93.9)

367 (91.4)

2.1E−04

4.4E−01

5.7E−02

  1. 1Data reported as median and IQR
  2. 2This column represents the data from the entire SLE cohort including the aPL+ and SSA/SSB+ SLE subgroups
  3. 3p value obtained by Wilcoxon rank-sum test or Fisher’s exact test. p values < 0.05 are highlighted in italics